Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer

Ding, Wenli; Zhang, Kexin; Li, Qinying; Xu, Linfei; Ma, Yanhui; Han, Fang; Zhu, Liang; Sun, Xiaodong

doi:10.1089/cell.2022.0133

Cited by 3 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, MSC-based therapy can modulate both the expression of miR-193b-5p, leading to the attenuation of sepsisinduced acute lung injury [176], and the polarization of lung macrophages and exerts antiasthmatic effects [177]. Moreover, there is an increase interest toward using MSCs in innovative gene vectors or drugs for cancer treatments [178].…”

Section: Most Recent Progress In the Application Of Mesenchymal Strom...mentioning

confidence: 99%

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Yuan

2024

Am J Stem Cells

View full text Add to dashboard Cite

Recent studies demonstrated that mesenchymal stem cells (MSCs) are important for the cell-based therapy of diseased or injured lung due to their immunomodulatory and regenerative properties as well as limited side effects in experimental animal models. Preclinical studies have shown that MSCs have also a remarkable effect on the immune cells, which play major roles in the pathogenesis of multiple lung diseases, by modulating their activity, proliferation, and functions. In addition, MSCs can inhibit both the infiltrated immune cells and detrimental immune responses in the lung and can be used in treating lung diseases caused by a virus infection such as Tuberculosis and SARS-COV-2. Moreover, MSCs are a source for alveolar epithelial cells such as type 2 (AT2) cells. These MSC-derived functional AT2-like cells can be used to treat and diminish serious lung disorders, including acute lung injury, asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis in animal models. As an alternative MSC-based therapy, extracellular vesicles that are derived from MSC-derived can be employed in regenerative medicine. Herein, we discussed the key research findings from recent clinical and preclinical studies on the functions of MSCs in treating some common and well-studied lung diseases. We also discussed the mechanisms underlying MSC-based therapy of well-studied lung diseases, and the recent employment of MSCs in both the attenuation of lung injury/inflammation and promotion of the regeneration of lung alveolar cells after injury. Finally, we described the role of MSC-based therapy in treating major pulmonary diseases such as pneumonia, COPD, asthma, and idiopathic pulmonary fibrosis (IPF).

show abstract

Section: Most Recent Progress In the Application Of Mesenchymal Strom...mentioning

confidence: 99%

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Yuan

2024

Am J Stem Cells

View full text Add to dashboard Cite

show abstract

Mesenchymal Stem Extracellular Vesicles in Various Respiratory Diseases: A New Opportunity

Hu,

Zhu,

Zhu

et al. 2024

JIR

View full text Add to dashboard Cite

Lung diseases are associated with high morbidity and mortality rates, thereby jeopardizing human health and imposing a great burden on society. Currently, lung diseases are mainly treated with medications, oxygen therapy and mechanical ventilation, but these approaches are unable to effectively reduce the mortality rate. Therefore, lung transplantation remains the ultimate treatment for various chronic lung diseases, but this treatment is also hindered by the limited availability of lung sources, immature technology and a low survival rate after transplantation. With constant changes in the environment, pathogens, type and amount of harmful substances and the prevalence of respiratory diseases, there is an urgent need to identify alternative treatment methods. Research on stem cell therapy has been very successful in recent years, and mesenchymal stem cells (MSCs), together with their secretory bodies, play a significant therapeutic role. Extracellular vesicles of MSCs (MSC-EVs) are also major components of the paracrine secretion of MSCs, including exosomes, microvesicles, and apoptotic bodies, among which exosomes are the most typical. MSC-EVs are believed to be present in various tissues of the human body where they can carry proteins, DNA, RNA and biologically active factors, just to name a few. They can also transmit various biological signals to participate in different biological activities, including the maintenance of homeostasis within the tissue. Several studies have further demonstrated that MSCs and their generated extracellular vesicles play an important role in the treatment of diseases. In this paper, the origin, properties and roles of MSCs and MSC-EVs are reviewed, the mechanisms of different lung diseases, the limitations of current therapeutic options and the roles of MSC-EVs in Chronic Obstructive Pulmonary Disease, asthma, infectious lung disease, lung cancer, pulmonary fibrosis, pulmonary arterial hypertension, and acute lung injury/ acute respiratory distress syndrome are also discussed ( Figure 1 ). In addition, the current limitations and possible future research directions are also discussed in view of providing new ideas for the role of MSC-EVs in the treatment of lung diseases.

show abstract

Non-small cell lung cancer cells and concomitant cancer therapy induce a resistance-promoting phenotype of tumor-associated mesenchymal stem cells

Sentek,

Braun,

Budeus

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionThe tumor microenvironment gained attraction over the last decades as stromal cells significantly impact on tumor development, progression and metastasis, and immune evasion as well as on cancer therapy resistance. We previously reported that lung-resident mesenchymal stem cells (MSCs) were mobilized and activated in non-small cell lung cancer (NSCLC) progression and could even mediate radiation resistance in co-cultured NSCLC cells.MethodsWe investigated how MSCs were affected by NSCLC cells in combination with cancer (radiation) therapy in indirect co-cultures using tumor-conditioned medium and Transwells or direct three-dimensional NSCLC–MSC spheroid co-cultures in order to unravel the resistance-mediating action of tumor-associated MSCs.ResultsAlthough no obvious phenotypic and functional alterations in MSCs following NSCLC co-culture could be observed, MSC senescence was induced following co-applied radiotherapy (RT). Global gene expression profiling, in combination with gene set enrichment analysis upon treatment, was used to confirm the senescent phenotype of irradiated MSC and to reveal relevant senescence-associated secretory phenotype (SASP) factors that could meditate NSCLC RT resistance. We identified senescent tumor-associated MSC-derived serine proteinase inhibitor (serpin) E1/PAI1 as potential SASP factor mediating NSCLC progression and RT resistance.DiscussionSpecified intra-tumor–stroma interactions and cell type-specific pro-tumorigenic functions could not only improve lung cancer classification but could even be used for a more precise profiling of individual patients, finally paving an additional way for the discovery of potential drug targets for NSCLC patients.

show abstract

Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer

Cited by 3 publications

References 90 publications

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Mesenchymal Stem Extracellular Vesicles in Various Respiratory Diseases: A New Opportunity

Non-small cell lung cancer cells and concomitant cancer therapy induce a resistance-promoting phenotype of tumor-associated mesenchymal stem cells

Contact Info

Product

Resources

About